BSX Boston Scientific Corporation Common Stock

NYSE · Health Care · Wyświetl na SEC EDGAR ↗
$49,42
Cena · Sie 21, 2026
Dane fundamentalne na dzień Sie 3, 2026
Zakres 52 tyg.
$42–$110
11% of range
Ocena Analityków
BUY
38 analysts
Cena Docelowa
$63
+27% upside
P/E (TTM)
49.1
ROE
12.6%
Marża Zysku Netto
14.4%

O Boston Scientific Corporation Common Stock Przegląd firmy z Wikipedii

Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Czytaj więcej

Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator (ICD) called the EMBLEM subcutaneous implantable defibrillator (S-ICD).

Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.

BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.

History

Boston Scientific was formed on June 29, 1979, in Watertown, Massachusetts, as a holding company for the medical products company Medi-Tech, Inc., and to position the company for growth in interventional medicine. Medi-Tech was the brainchild of Itzhak Bentov, a Czech-born émigré to Israel and then to the United States, who worked at the Arthur D. Little think tank in Cambridge, Massachusetts, and ran a contract research company from his rented house in Belmont, Massachusetts, a venture he founded in 1965 with a business friend, Dan Singer.

In 1967 Bentov was asked by Boston Beth Israel Hospital radiologists to design a steerable, remotely controlled catheter; a series of engineering designs, polymer improvements and prototypes led to the release of a new steerable angiography catheter in 1969. That year John Abele joined the small company with an option to buy. A year later he exercised his option with Cooper Labs as a business partner, and the operation was moved – out of Bentov's lab in the basement of the rectory of a Catholic church in Belmont – to Watertown.

After a decade of steady growth, Abele met Pete Nicholas by chance in their neighborhood in Concord, Massachusetts. Their partnership hinged on Nicholas' goal to build business enterprises and Abele's predilection for the vision and potential in noninvasive surgical instrumentation; they gathered backers in the Boston banking community to buy out the Cooper Labs interest and form the new corporation.

Less than a year later Kimray Medical Associates (later Mansfield Scientific, Inc.) was acquired, adding vena cava filters and cardiac output computers to the product line. By 1982 a renovated mill building in Watertown was transformed into a manufacturing plant. Acquisitions continued, with Endo-Tech (Microvasive, Inc.: gastrointestinal and pulmonary) in 1981 and then Van-Tec (urology) in 1988, and an international presence was expanded. Mansfield Scientific, Microvasive, and Medi-Tech merged into Boston Scientific December 31, 1988.

Initial public offering (1992)

On May 19, 1992, Boston Scientific launched an initial public offering of 23.5 million shares, of which 18.8 million were offered in the U.S. and 4.7 million were offered outside the U.S. The initial offering amounted to 23% of Boston Scientific's outstanding stock.

Goldman, Sachs & Co. (lead) and PaineWebber Inc. were the underwriters and Abbott Laboratories held a 20% stake (23.5 million shares). The market capitalization was about $1.6 billion. The U.S. shares were listed on the New York Stock Exchange.

Post–IPO

From 1995 through 1997, Boston Scientific increased its technology R&D and product offerings following substantial acquisitions that included Cardiovascular Imaging Systems (intravascular ultrasound), SCIMED (cardiovascular), Vesica Medical (urology), Meadox (textile vascular prostheses), EP Technologies (cardiac ablation controllers), MinTec (abdominal aortic aneurysm grafts), Symbiosis Corporation (specialty medical product manufacture).

On November 3, 1998, Boston Scientific restated its financial results for 1997, as well as its quarterly results for the first three quarters of 1998, due to the occurrence of business irregularities in the operations of its Japanese subsidiary.

In 2001, Boston Scientific acquired Target Therapeutics (neurology) in a tax-free stock swap for about $1.1 billion, more than 10 times Target's total sales, in contrast to the usual multiple of 10 times earnings.

The Taxus Stent was approved in 2003 in Europe and other countries and, in the United States, by the FDA in March 2004. It was the second drug-eluting stent approved in the United States.

In April 2004, the company announced that it had exercised an exclusive option to acquire Precision Vascular Systems, Inc., as part of a series of agreements between Boston Scientific and Precision Vascular in 2002, for an undisclosed sum. In June, Boston Scientific acquired Advanced Bionics Corporation for $740 million in cash, plus earn out payments. In December, Boston Scientific completed its acquisition of Advanced Stent Technologies, Inc., for $120 million payable in Boston Scientific stock, plus the possibility of future contingent payments. AST had been developing stent and stent delivery systems specifically designed to address the anatomical needs of coronary artery disease in bifurcated vessels.

In April 2005, BSC exercised an exclusive option to acquire TriVascular, Inc., for an undisclosed sum and renamed it as Boston Scientific Santa Rosa Corporation, or BSSR. TriVascular was founded in January 1998 to develop less-invasive medical devices and procedures for treating abdominal aortic aneurysms, but BSC discontinued its endovascular aortic repair (EVAR) program in 2006. BSC also announced it had exercised its option to acquire CryoVascular Systems, Inc., and its proprietary angioplasty device to treat atherosclerotic disease of the legs and other peripheral arteries. In June Boston Scientific announced that its wholly owned subsidiary, Nemo I Acquisition, Inc., had successfully acquired Salt Lake City-based Rubicon Medical Corporation, with Rubicon became a wholly owned subsidiary of Boston Scientific.

In March 2008, BSC sold BSSR to TV2 Holding Company of Santa Rosa. Terms of the sale include $30 million in cash paid at the closing to BSC and a warrant allowing BSC to purchase a minority interest in TV2.

Guidant merger

In January 2006, the company announced an offer for its longtime competitor, Guidant, for $72 per share or $25 billion. The offer, however, was rejected. On April 21, 2006, BSC acquired Guidant for $27.2 billion. Guidant was split between BSC and Abbott Laboratories. Four years later, in 2010, when moving its heart-rhythm business from its acquisition of Guidant, Boston Scientific eliminated 1300 jobs.

Post-merger

In December 2007, Boston Scientific announced it would sell its Fluid Management and Venous Access businesses for $425 million to Avista Capital Partners.

In April 2008, the company acquired CryoCor, Inc., for $1.35 per share, $17.6 million in total. Navilyst Medical was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units.

In January 2009, Boston announced it would acquire Labcoat Limited, whose primary development was that of a development-stage drug-eluting stent – for an undisclosed sum.

2010–2020

In October 2010, the company was fined $600,000 by the US Department of Justice for paying a US Army doctor to use their devices and recommend them to others. In the same month Boston Scientific acquired Asthmatx, Inc., for $193.5 million, with payments of up to $250 million being paid on the achievement of specified revenue-based criteria through 2019.

In January 2011, Boston acquired Atritech, Inc., for $100 million, plus up to $275 million in additional potential payments. In the same month, Boston Scientific acquired Intelect Medical, Inc., for $78 million and the remaining 86% of Sadra Medical, Inc., not already owned for $193 million plus contingent payments. At the same time, the business divested its neurovascular business to Stryker Corporation for $1.5 billion.

In June 2012, Boston Scientific officially acquired Cameron Health for a total sum of $1.3 billion, paid out incrementally as various revenue milestones were achieved. In September, the company announced it would acquire BridgePoint Medical, Inc., developer of a catheter-based system to treat coronary chronic total occlusions. In October, the company acquired Rhythmia Medical, Inc., developer of mapping and navigation methods for use in cardiac catheter ablations and other electrophysiology procedures. A month later, the business acquired catheter-based renal denervation system developer, Vessix Vascular, Inc.

In November 2013, Boston announced it would acquire Bard EP, the electrophysiology business of C.R. Bard, Inc. for $275 million.

In May 2014, Boston acquired hysteroscopic intrauterine tissue removal specialist, IoGyn, Inc. In September, the business announced it would acquire the Interventional business of Bayer.

In March 2015, the company announced it would acquire Endo International Plc's American Medical Systems urology business for at least $1.6 billion, expanding the company's health and prostate treatments. In April, Boston announced its intention to acquire Xlumena, Inc. In October Boston announced it had invested further in percutaneous mitral valve replacement system developer, MValve Technologies, gaining a right to acquire the business in the future.

In July 2016, the business acquired the manufacturer of radiofrequency ablation systems, Cosman Medical, Inc. In September, Boston Scientific announced it had acquired EndoChoice Holdings, Inc., becoming part of the Boston Scientific Endoscopy business for $210 million. In November, the company acquired the gynecology and urology portfolio of Distal Access, LLC, a company that designs minimally invasive medical devices. In December 2016, the business acquired a 15% stake in Neovasc, Inc., for $75 million.

In 2016, Boston Scientific acquired EndoChoice, located in Alpharetta, Georgia.

In May 2017, the company acquired Symetis SA, a developer of minimally invasive transcatheter aortic valve implantation devices. In October, Boston acquired Apama Medical Inc. for up to $300 million.

In April 2018, Boston Scientific announced the triple closure of its acquisitions of women's health company, nVision Medical Corporation, NxThera and Securus Medical Group, Inc., for up to $50 million. In July, Boston Scientific announced it would acquire Cryterion Medical, Inc, Veniti, Inc., in August Augmenix, Inc., and Claret Medical, Inc. In November, Boston Scientific announced it would acquire UK medical device maker BTG plc for $4.2 billion. In late December, the company announced it would acquire Millipede, Inc for $325 million, after previously investing $90 million in the company.

In May 2019, the company announced it would acquire Vertiflex, Inc., with the aim of increasing its interventional pain therapy offerings. Vertiflex principally developed treatment for lumbar spinal stenosis.

2021–present

In January 2021, Boston announced it would acquire Minneapolis-based Preventice Solutions, Inc., and its portfolio of mobile cardiac health solutions for up to $1.2 billion. In March, the business announced it would acquire the surgical business part of Lumenis Ltd. for $1 billion from an affiliate of Baring Private Equity Asia, who, in 2019, had acquired Lumenis from XIO Group. In June, the company announced it would acquire the 73% of Farapulse, Inc., it did not already own, for $295 million. Farapulse was a University of Iowa startup. In September, the business announced it would acquire Devoro Medical, Inc., and its blood clot capturing technology. Boston Scientific had been a strategic investor in Devoro since 2019. In October, the company announced it would acquire Baylis Medical Company Inc. for $1.75 billion, expanding its electrophysiology and heart product portfolios (see Frank Baylis).

In June 2022, the Boston Scientific announced it would acquire M.I.Tech Co., Ltd., of South Korea, for around $230 million. The deal was cancelled in May 2023 citing regulatory hurdles. In August, Boston announced it would acquire Obsidio, Inc.

In June 2022, Boston Scientific announced that it would invest $62.5 million in a manufacturing and supply chain facility in Johns Creek, Georgia, a suburb of Atlanta.

In September 2023, Boston Scientific acquired Relievant Medsystems, Inc. for an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years.

In January 2024, the company announced it would acquire Axonics, Inc. for $3.7 billion.

In January 2026, Boston Scientific announced it would acquire Penumbra in a ~$15 billion cash and stock deal. The deal was expected to close by yearend.

Corporate governance

Michael F. Mahoney is the current Boston Scientific chairman and chief executive officer.

Organizational culture

The journal US Black Engineer & Information Technology (USBE & IT), in its "2021 Top Supporters of HBCU Engineering," ranked BSC No. 6 among the "Top 20 Industry Supporters."

Financials

Litigation

Johnson & Johnson patent litigation

Beginning in 2003, Boston Scientific and Johnson & Johnson were involved in a series of litigations involving patents covering heart stent medical devices. Both parties claimed that the other had infringed upon their patents. The litigation was settled once Boston Scientific agreed to pay $716 million to Johnson & Johnson in September 2009 and an additional $1.73 billion in February 2010.

It was announced in November 2014 that Johnson & Johnson would have another chance for payback after a multibillion-dollar trial was set for November 20, 2014. A New York federal court judge would hear the case without a jury to decide whether Boston Scientific should be held liable for the contract breach.

Transvaginal mesh

Boston Scientific is one of several manufacturers of a medical device called transvaginal mesh, a type of surgical mesh used to treat pelvic organ prolapse. Experts concluded that the medical company had used cheap, counterfeit resin, which was both toxic and degraded when exposed to oxygen. When this was announced on 60 Minutes, Boston Scientific responded by saying the broadcast was "irresponsible and misleading," citing a 2017 Food and Drug Administration (FDA) report stating that although they found variability in the polypropylene resin, "these differences do not present new safety or effectiveness concerns." One woman, who sued in 2011, was awarded $100 million. Two operations had failed to remove all the parts of the mesh and she was still in pain. The company appealed the decision and had the amount reduced to $10M. In 2015, Boston Scientific announced it would pay $119 million to 2,970 lawsuit plaintiffs, who had been injured by the mesh. On March 23, 2021, the company agreed to pay $189 million to settle allegations that it had seriously misrepresented the risks related to the vaginal mesh. As of Jan. 27, 2021, around 54,000 lawsuits related to transvaginal meshes had been filed against Boston Scientific.

In April 2019, the FDA ordered Boston Scientific and Coloplast to remove all of their vaginal mesh products from the United States market. In 2020, Johnson & Johnson was required to pay $344 million for failing to disclose the serious product risks of its transvaginal mesh product.

NIR stent

In 2005, Boston Scientific paid $74 million to settle allegations that it had continued to sell NIR stents (flexible stents) after learning that many of them were defective. Twenty-six injuries and one death may have been caused by malfunctioning stents.

Defective defibrillators

In 2011, Guidant, a subsidiary of Boston Scientific, was criminally convicted of a failure to report defibrillator safety problems to the FDA. The company was forced to pay more than $296 million in criminal fines and had to submit to the supervision of the U.S. Probation Office for three years.

Even though Guidant knew the devices were defective, they continued to sell the defibrillators anyway. Guidant LLC had also advised its sales representatives to tell physicians that nothing was wrong with the defibrillators, and told the FDA that the proposed corrections were not being done to correct life-threatening device flaws, but were rather to improve process throughout. Not until three deaths had occurred and ten months had passed did the company reveal the defects in 2005. The directives for these wrongdoings had been implemented prior to Boston Scientific's acquisition of Guidant in 2006.

In 2013, BSC and three of its subsidiaries – Guidant LLC, Guidant Sales LLC, and Cardiac Pacemakers, Inc. – agreed to pay $30 million to settle allegations that, according to the Justice Department, between 2002 and 2005, Guidant knowingly sold defective heart devices to health care facilities that in turn implanted the devices into Medicare patients.

Bribery allegations

In 2009, Boston Scientific agreed to pay $22 million to settle allegations that its subsidiary Guidant LLC had used kickback schemes to boost sales for its pacemakers (cardiac rhythm management or CRM devices) and defibrillators (implantable cardioverter-defibrillators or ICD devices). Allegedly, Guidant paid doctors between $1,000 and $1,500 each to participate in one of its four post-studies known as RaCE ($1,500), RaCE II ($1,000), RaCE III ($1,000), and MERITS ($1,000).

Obsidio Embolic recall

In April 2024, the FDA announced a recall of Boston Scientific's device Obsidio Embolic, which is used to stop hemorrhaging and excessive bleeding. It has been found that when the device is paired with the aliquot technique, it can lead to bowel ischemia, which can mean longer hospitalization or death for patients.

Notable people

Donald Steven Baim, MD (1946–2009), served Chief Medical and Scientific Officer for Boston Scientific from 2006 until his death in 2009.

Ian Meredith, MD, PhD, AM (born 1956), was Global Chief Medical Officer and Executive Vice President from 2017 to 2023.

Ursula Burns (born 1958), who served as a Member of Boston Scientific's 13-seat Board of Directors since 2002, resigned after being named Chief Executive Officer of the Xerox Corporation, taking effect July 1, 2009, and becoming the first African-American female CEO of a Fortune 500 company.

Kristina M. Johnson (born 1957), PhD, who served as a Member of BSC's Board since May 2006, resigned in May 2009 after being confirmed by the U.S. Senate to serve as Under Secretary in the Department of Energy (see Under Secretary of Energy for Infrastructure & Under Secretary of Energy for Science and Innovation). Johnson was re-elected to BSC's board January 1, 2011, and served in that position until May 2017.

Yoshiaki Fujimori (born 1951), BSC Board Member since July 2016.

James Robert Tobin Jr. (born 1944), President & CEO of BSC from 1999 through 2009.

John Raymond Elliott "Ray" (born 1950), served as a Board Member from September 2007 to 2009, then, in July 2009, re-joined the Board and became President & CEO, a position he held until December 31, 2011. Before, he had served as Chairman of Zimmer Holdings, Inc., from August 6, 2001, to November 30, 2007, and President & CEO from March 20, 2001, to May 2007.

Headquarters and regional centers

World headquarters: Marlborough, Massachusetts

Europe headquarters: Voisins-le-Bretonneux, France

Asia Pacific headquarters: Boston Scientific Asia Pacific Pte Ltd., Singapore

U.S. Government Affairs office: Washington, D.C.

Latin America headquarters: Weston, Florida

Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗

Wikidata ↗

BSX Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy

Cena
$49.42
Kapitalizacja Rynkowa
—
P/E (TTM)
49.1
EPS (TTM)
$1.94
Przychody (TTM)
$20.07B
Stopa dywidendy
—
ROE
12.6%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$42 – $110

BSX Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok

Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS

Przychody i Zysk Netto $20.07B
10-point trend, +139.4%
2016-12-31 → 2025-12-31
EPS $1.94
10-point trend, +676.0%
2016-12-31 → 2025-12-31
Wolny przepływ pieniężny $3.66B
8-point trend, +230.4%
2017-12-31 → 2025-12-31
Marże 14.4%
8-point trend, -3.3%
2017-12-31 → 2025-12-31

Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?

Wskaźnik
Trend 5-letni
BSX
Mediana porównawcza
P/E (TTM)
5-point trend, -20.2%
49.1
26.3

Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC

Wskaźnik
Trend 5-letni
BSX
Mediana porównawcza
Gross Margin (Marża brutto)
5-point trend, +6.1%
69.0%
63.1%
Operating Margin (Marża Operacyjna)
5-point trend, +2322.2%
18.0%
—
Net Profit Margin (Marża Zysku Netto)
5-point trend, +1836.1%
14.4%
15.6%
ROA
5-point trend, +2677.8%
7.0%
7.6%
ROE
5-point trend, +2471.7%
12.6%
15.0%
ROIC
5-point trend, +2459.3%
12.7%
—

Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu

Wskaźnik
Trend 5-letni
BSX
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
5-point trend, -11.1%
1.6
1.7
Quick Ratio (Wskaźnik Szybkości)
5-point trend, -23.3%
0.4
—

Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni

Wskaźnik
Trend 5-letni
BSX
Mediana porównawcza
Revenue YoY (Przychody R/R)
5-point trend, +68.9%
19.9%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
5-point trend, +68.9%
16.5%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
5-point trend, +68.9%
15.2%
—
EPS YoY
5-point trend, +181.2%
55.2%
—
Net Income YoY (Zysk Netto R/R)
5-point trend, +177.8%
56.7%
—

Wskaźniki na akcję EPS, wartość księgowa na akcję, przepływy pieniężne na akcję, dywidenda na akcję

Wskaźnik
Trend 5-letni
BSX
Mediana porównawcza
EPS (Diluted) (EPS (Rozwodniony))
5-point trend, +181.2%
$1.94
—

Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności

Wskaźnik
Trend 5-letni
BSX
Mediana porównawcza

BSX Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu

KUP 38 analityków
  • Mocne kupno 11 28,9%
  • Kup 19 50,0%
  • Trzymaj 8 21,1%
  • Sprzedaj 0 0,0%
  • Mocna sprzedaż 0 0,0%

12-miesięczny cel cenowy

29 analityków · 2026-08-19
Średni cel $60.00 +21,4%
Średnia cel $62.69 +26,9%

Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników

Średnie zaskoczenie
0.03%
Okres EPS Actual EPS Szacowany Niespodzianka
30 czerwca 2026 $0.86 $0.84 0.02%
31 marca 2026 $0.80 $0.79 0.01%
31 grudnia 2025 $0.80 $0.79 0.01%
30 września 2025 $0.75 $0.72 0.03%
30 czerwca 2025 $0.75 $0.73 0.02%
31 marca 2025 $0.75 $0.68 0.07%

Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora

Ticker Kapitalizacja Rynkowa P/E Przychody r/r Marża Netto ROE Marża brutto
BSX — 49.1 19.9% 14.4% 12.6% 69.0%
ABT $250.18B 33.7 5.7% 14.7% 13.1% —
ISRG $201.11B 72.0 20.5% 28.4% 16.7% 66.0%
SYK $134.44B 41.8 11.2% 12.9% 15.1% 64.0%
EW $49.50B 46.6 11.6% 17.7% 10.6% 78.0%
BDX — 25.3 8.2% 7.7% 6.5% —
IDXX $53.93B 51.7 10.4% 24.6% 69.2% 61.8%
DXCM $25.54B 31.8 15.6% 17.9% 31.4% 60.1%
GEHC — 18.0 4.8% 10.1% 22.1% 40.0%
RMD $28.11B 18.7 9.8% 26.9% 23.6% 61.1%
ZBH $28.66B 25.3 7.2% 8.6% 5.6% —

Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne

Rachunek zysków i strat 16
Dane roczne Rachunek zysków i strat dla BSX
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +169.0% $20.07B $16.75B $14.24B $12.68B $11.89B $9.91B $10.73B $9.82B $9.05B $8.39B $7.48B $7.46B
Cost of Revenue 12-point trend, +181.5% $6.22B $5.26B $4.34B $3.96B $3.71B $3.46B $3.12B $2.81B $2.59B $2.42B $2.17B $2.21B
Gross Profit 12-point trend, +168.0% $13.85B $11.49B $9.90B $8.73B $8.18B $6.45B $7.62B $7.01B $6.46B $5.96B $5.30B $5.17B
SG&A Expense 12-point trend, +137.3% $6.89B $5.98B $5.19B $4.52B $4.36B $3.79B $3.94B $3.57B $3.29B $3.10B $2.87B $2.90B
Operating Expenses 12-point trend, +87.2% $10.24B $8.89B $7.55B $7.08B $6.98B $6.53B $6.10B $5.50B $5.17B $5.51B $5.59B $5.47B
Operating Income 12-point trend, +1300.3% $3.61B $2.60B $2.34B $1.65B $1.20B $-80M $1.52B $1.51B $1.28B $447M $-283M $-301M
Interest Expense 12-point trend, +61.6% $349M $305M $265M $470M $341M $361M $473M $241M $229M $233M $284M $216M
Other Non-op 12-point trend, -2950.0% $-228M $-321M $-358M $-508M $218M $362M $-358M $156M $-124M $-37M $-83M $8M
Pretax Income 12-point trend, +765.0% $3.38B $2.28B $1.99B $1.14B $1.08B $-79M $687M $1.42B $933M $177M $-650M $-509M
Income Tax 12-point trend, +226.4% $493M $436M $393M $443M $36M $2M $-4.01B $-249M $828M $-170M $-411M $-390M
Net Income 12-point trend, +2530.3% $2.89B $1.85B $1.59B $698M $1.04B $-82M $4.70B $1.67B $104M $347M $-239M $-119M
EPS (Basic) 12-point trend, +2277.8% $1.96 $1.26 $1.08 $0.45 $0.69 $-0.08 $3.38 $1.21 $0.08 $0.26 $-0.18 $-0.09
EPS (Diluted) 12-point trend, +2255.6% $1.94 $1.25 $1.07 $0.45 $0.69 $-0.08 $3.33 $1.19 $0.08 $0.25 $-0.18 $-0.09
Shares (Basic) 12-point trend, +11.8% 1,480,400,000 1,471,500,000 1,453,000,000 1,430,500,000 1,422,300,000 1,416,700,000 1,391,500,000 1,381,000,000 1,370,100,000 1,357,600,000 1,341,200,000 1,324,300,000
Shares (Diluted) 12-point trend, +12.9% 1,494,500,000 1,485,900,000 1,463,500,000 1,439,700,000 1,433,800,000 1,416,700,000 1,410,600,000 1,401,400,000 1,392,700,000 1,377,200,000 1,341,200,000 1,324,300,000
EBITDA 10-point trend, +1074.8% $4.98B $3.87B · $2.79B $2.29B $1.04B $2.53B $2.40B $2.13B · $442M $424M
Bilans 27
Dane roczne Bilans dla BSX
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +234.8% $1.97B $414M $865M $928M $1.93B $1.73B $217M $146M $188M $196M $319M $587M
Inventory 12-point trend, +211.1% $2.94B $2.81B $2.48B $1.87B $1.61B $1.35B $1.58B $1.17B $1.08B $955M $1.02B $946M
Prepaid Expense 12-point trend, +49.0% $660M $831M $621M $731M $799M $751M $880M $921M $942M $541M $365M $443M
Other Current Assets 9-point trend, +227.2% · $831M $621M $731M $799M $751M $880M $921M · $240M $254M ·
Current Assets 12-point trend, +143.9% $8.79B $6.92B $6.51B $5.76B $6.32B $6.69B $4.70B $4.00B $3.82B $3.24B $3.47B $3.61B
PP&E (Net) 12-point trend, +167.8% $4.04B $3.29B $2.86B $2.45B $2.25B $2.08B $2.08B $1.78B $1.70B $1.63B $1.49B $1.51B
PP&E (Gross) 12-point trend, +98.8% $7.64B $6.83B $6.34B $5.73B $5.53B $5.31B $5.17B $4.74B $4.62B $4.37B $4.06B $3.85B
Accum. Depreciation 12-point trend, +54.3% $3.61B $3.53B $3.48B $3.28B $3.27B $3.22B $3.09B $2.96B $2.93B $2.73B $2.57B $2.34B
Goodwill 12-point trend, +210.0% $18.28B $17.09B $14.39B $12.92B $11.99B $9.95B $10.18B $7.91B $7.00B $6.68B $6.47B $5.90B
Intangibles 12-point trend, +25.2% $7.02B $6.68B $6.00B $5.90B $6.12B $5.92B $7.89B $6.37B $5.84B $5.88B $6.19B $5.61B
Other Non-current Assets 12-point trend, +191.2% $1.19B $1.75B $1.53B $1.50B $1.41B $1.92B $1.53B $845M $688M $666M $505M $407M
Total Assets 12-point trend, +156.5% $43.67B $39.40B $35.14B $32.47B $32.23B $30.78B $30.57B $21.00B $19.04B $18.10B $18.13B $17.02B
Accounts Payable 12-point trend, +336.6% $1.14B $960M $942M $862M $794M $513M $542M $349M $530M $447M $209M $262M
Accrued Liabilities 12-point trend, +64.2% $3.20B $2.77B $2.65B $2.16B $2.44B $2.20B $2.11B $2.25B $2.46B $2.31B $1.97B $1.95B
Current Liabilities 12-point trend, +91.1% $5.44B $6.40B $4.93B $3.80B $4.27B $3.68B $4.87B $5.26B $5.65B $3.59B $2.43B $2.85B
Capital Leases 8-point trend, +446000000.00 $446M $401M $390M $347M $389M $401M $276M $0 · · · ·
Deferred Tax 12-point trend, -81.9% $220M $155M $134M $144M $310M $330M $595M $328M $191M $18M $735M $1.21B
Other Non-current Liabilities 12-point trend, -9.8% $2.40B $1.87B $1.97B $2.04B $2.22B $2.31B $2.63B $1.88B $2.37B $2.34B $2.97B $2.67B
Long-term Debt 4-point trend, -9.2% · · · · · · · · $3.81B $5.42B $5.65B $4.20B
Total Debt 2-point trend, -100.0% · · · · · · · · · · $0 $400M
Common Stock 12-point trend, +6.2% $17M $17M $17M $17M $17M $17M $16M $16M $16M $16M $16M $16M
Retained Earnings 12-point trend, +164.1% $5.57B $2.67B $819M $-750M $-1.39B $-2.38B $-2.25B $-6.95B $-8.39B $-8.58B $-8.93B $-8.69B
Treasury Stock 12-point trend, +31.1% $2.25B $2.25B $2.25B $2.25B $2.25B $2.25B $1.72B $1.72B $1.72B $1.72B $1.72B $1.72B
AOCI 12-point trend, -523.6% $-610M $275M $49M $269M $263M $207M $270M $33M $-59M $1M $88M $144M
Stockholders' Equity 12-point trend, +275.3% $24.23B $21.77B $19.28B $17.57B $16.62B $15.33B $13.88B $8.73B $7.01B $6.73B $6.32B $6.46B
Liabilities + Equity 12-point trend, +156.5% $43.67B $39.40B $35.14B $32.47B $32.23B $30.78B $30.57B $21.00B $19.04B $18.10B $18.13B $17.02B
Shares Outstanding 6-point trend, +5.1% · · · · · · 1,394,922,641 1,384,581,760 1,373,496,628 1,362,104,547 1,346,647,516 1,327,451,966
Przepływy pieniężne 19
Dane roczne Przepływy pieniężne dla BSX
Wskaźnik Trend 202520242023202220212020201920182017201620152014
D&A 12-point trend, +88.7% $1.37B $1.27B $1.20B $1.14B $1.09B $1.12B $1.01B $894M $844M $815M $769M $725M
Stock-based Comp 12-point trend, +190.3% $299M $266M $233M $220M $194M $170M $157M $140M $127M $116M $107M $103M
Deferred Tax 12-point trend, +97.6% $-12M $-90M $73M $-7M $-142M $-85M $-4.29B $-162M $244M $-343M $-605M $-494M
Amort. of Intangibles 12-point trend, +104.8% $897M $856M $828M $803M $741M $789M $699M $599M $565M $545M $495M $438M
Restructuring 12-point trend, +46.4% $101M $16M $69M $24M $40M $52M $38M $36M $37M $28M $26M $69M
Other Non-cash 10-point trend, -101.2% $-13M $144M · $-521M $-316M $382M $256M $-2.23B $107M · $568M $1.05B
Operating Cash Flow 12-point trend, +257.3% $4.53B $3.44B $2.50B $1.53B $1.87B $1.51B $1.84B $310M $1.43B $1.18B $691M $1.27B
CapEx 12-point trend, +238.2% $876M $790M $711M $588M $554M $376M $461M $316M $319M $376M $247M $259M
Investing Cash Flow 12-point trend, -254.4% $-2.64B $-5.69B $-2.57B $-2.01B $-1.60B $-411M $-5.04B $-1.92B $-1.01B $-887M $-2.19B $-745M
Net Debt Issued 5-point trend, -3560000000.00 · · · · · · $-3.56B $-602M $-1.00B · $-1.15B $0
Stock Issued 9-point trend, -100.0% · · · $0 $0 $975M $0 $0 $85M $111M $114M $60M
Stock Repurchased 8-point trend, -100.0% · · · $0 $0 $535M $0 $0 · $0 $0 $125M
Net Stock Activity 8-point trend, +100.0% · · · $0 $0 $440M $123M $101M $85M · $114M $-65M
Dividends Paid 7-point trend, +0.00 · $0 $28M $55M $55M $28M $0 $0 · · · ·
Financing Cash Flow 12-point trend, -163.3% $-395M $1.81B $5M $-548M $-95M $293M $2.97B $1.43B $110M $-206M $1.28B $-150M
Net Change in Cash 11-point trend, +316.5% $1.54B $-450M $-70M $-1.04B $173M $1.39B $-222M $-188M · $-123M $-268M $370M
Taxes Paid $561M · · · · · · · · · · ·
Free Cash Flow 10-point trend, +262.2% $3.66B $2.65B · $938M $1.32B $1.13B $1.38B $-6M $1.11B · $353M $1.01B
Levered FCF 10-point trend, +250.2% $3.36B $2.40B · $650M $986M $762M $-1.86B $-289M $1.08B · $249M $960M
Rentowność 8
Dane roczne Rentowność dla BSX
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Gross Margin 10-point trend, -0.4% 69.0% 68.6% · 68.8% 68.8% 65.0% 71.0% 71.4% 71.3% · 65.7% 69.3%
Operating Margin 10-point trend, +546.7% 18.0% 15.5% · 13.0% 10.1% -0.81% 14.1% 15.3% 14.2% · -4.0% -4.0%
Net Margin 10-point trend, +1006.3% 14.4% 11.0% · 5.5% 8.8% -0.83% 43.8% 17.0% 1.1% · -3.0% -1.6%
Pretax Margin 10-point trend, +347.2% 16.9% 13.6% · 9.0% 9.0% -0.80% 6.4% 14.5% 10.3% · -8.1% -6.8%
EBITDA Margin 10-point trend, +336.8% 24.8% 23.1% · 22.0% 19.3% 10.5% 23.6% 24.4% 23.5% · 5.5% 5.7%
ROA 10-point trend, +1080.3% 7.0% 5.0% · 2.2% 3.3% -0.27% 18.2% 8.3% 0.56% · -1.4% -0.71%
ROE 10-point trend, +786.9% 12.6% 8.7% · 4.0% 6.3% -0.53% 41.6% 21.2% 1.5% · -3.7% -1.8%
ROIC 10-point trend, +1336.9% 12.7% 9.7% · 5.7% 7.0% -0.54% 74.8% 20.3% 2.1% · -1.9% -1.0%
Płynność i wypłacalność 4
Dane roczne Płynność i wypłacalność dla BSX
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Current Ratio 10-point trend, +27.6% 1.6 1.1 · 1.5 1.5 1.8 1.0 0.8 0.7 · 1.4 1.3
Quick Ratio 10-point trend, +75.1% 0.4 0.1 · 0.2 0.5 0.5 0.0 0.0 0.0 · 0.1 0.2
Debt / Equity 2-point trend, -100.0% · · · · · · · · · · 0.0 0.1
Interest Coverage 10-point trend, +842.9% 10.4 8.5 · 3.5 3.5 -0.2 3.2 6.2 5.6 · -1.2 -1.4
Efektywność 2
Dane roczne Efektywność dla BSX
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Asset Turnover 10-point trend, +8.9% 0.5 0.4 · 0.4 0.4 0.3 0.4 0.5 0.5 · 0.5 0.4
Inventory Turnover 10-point trend, -9.8% 2.2 2.0 · 2.3 2.5 2.4 2.3 2.5 2.6 · 2.2 2.4
Na akcję 5
Dane roczne Na akcję dla BSX
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Book Value / Share 5-point trend, +104.5% · · · · · · $9.95 $6.30 $5.11 · $4.69 $4.86
Revenue / Share 10-point trend, +138.4% $13.43 $11.27 · $8.81 $8.29 $7.00 $7.61 $7.01 $6.50 · $6.02 $5.63
Cash Flow / Share 10-point trend, +216.6% $3.03 $2.31 · $1.06 $1.30 $1.06 $1.30 $0.22 $1.02 · $0.45 $0.96
Cash / Share 5-point trend, -64.8% · · · · · · $0.16 $0.11 $0.14 · $0.24 $0.44
EPS (TTM) 12-point trend, +2255.6% $1.94 $1.25 $1.07 $0.45 $0.69 $-0.08 $3.33 $1.19 $0.08 $0.25 $-0.18 $-0.09
Stopy Wzrostu 7
Dane roczne Stopy Wzrostu dla BSX
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, -0.3% 19.9% 17.6% 12.3% 6.7% 19.9% · · · · · · ·
Revenue CAGR 3Y 3-point trend, +28.9% 16.5% 12.1% 12.8% · · · · · · · · ·
Revenue CAGR 5Y 15.2% · · · · · · · · · · ·
EPS YoY 4-point trend, +258.7% 55.2% 16.8% 137.8% -34.8% · · · · · · · ·
EPS CAGR 3Y 2-point trend, +186.5% 62.7% 21.9% · · · · · · · · · ·
Net Income YoY 4-point trend, +272.0% 56.7% 16.0% 128.1% -33.0% · · · · · · · ·
Net Income CAGR 3Y 2-point trend, +188.1% 60.6% 21.0% · · · · · · · · · ·
Wycena (TTM) 16
Dane roczne Wycena (TTM) dla BSX
Wskaźnik Trend 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +169.0% $20.07B $16.75B $14.24B $12.68B $11.89B $9.91B $10.73B $9.82B $9.05B $8.39B $7.48B $7.46B
Net Income TTM 12-point trend, +2530.3% $2.89B $1.85B $1.59B $698M $1.04B $-82M $4.70B $1.67B $104M $347M $-239M $-119M
Market Cap 5-point trend, +258.6% · · · · · · $63.08B $48.93B $34.05B · $24.83B $17.59B
Enterprise Value 2-point trend, +40.9% · · · · · · · · · · $24.51B $17.40B
P/E 12-point trend, +133.4% 49.1 71.5 54.0 102.8 61.6 -449.4 13.6 29.7 309.9 86.5 -102.4 -147.2
P/S 5-point trend, +149.3% · · · · · · 5.9 5.0 3.8 · 3.3 2.4
P/B 5-point trend, +66.9% · · · · · · 4.5 5.6 4.9 · 3.9 2.7
P / Cash Flow 5-point trend, +147.9% · · · · · · 34.4 157.8 23.9 · 41.4 13.9
P / FCF 5-point trend, +163.4% · · · · · · 45.9 -8155.2 30.8 · 70.3 17.4
EV / EBITDA 2-point trend, +35.1% · · · · · · · · · · 55.5 41.0
EV / FCF 2-point trend, +303.0% · · · · · · · · · · 69.4 17.2
EV / Revenue 2-point trend, +40.6% · · · · · · · · · · 3.3 2.3
Dividend Yield Flat — no change across 2 periods · · · · · · 0.00% 0.00% · · · ·
Earnings Yield 12-point trend, +398.5% 2.0% 1.4% 1.8% 0.97% 1.6% -0.22% 7.4% 3.4% 0.32% 1.2% -0.98% -0.68%
Payout Ratio 4-point trend, +100.0% · 0.00% · 7.9% 5.3% -34.2% · · · · · ·
Annual Payout 7-point trend, +0.00 · $0 $28M $55M $55M $28M $0 $0 · · · ·

Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat

Rachunek zysków i strat
2025-12-312024-12-312023-12-312022-12-312021-12-31
Przychody $20.07B$16.75B$14.24B$12.68B$11.89B
Marża Brutto % 69.0%68.6%—68.8%68.8%
Marża Operacyjna % 18.0%15.5%—13.0%10.1%
Zysk netto $2.89B$1.85B$1.59B$698M$1.04B
Rozwodniony EPS $1.94$1.25$1.07$0.45$0.69
Bilans
2025-12-312024-12-312023-12-312022-12-312021-12-31
Wskaźnik bieżący 1.61.1—1.51.5
Wskaźnik Szybkości 0.40.1—0.20.5
Przepływy pieniężne
2025-12-312024-12-312023-12-312022-12-312021-12-31
Wolny przepływ pieniężny $3.66B$2.65B—$938M$1.32B

Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie

Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów

📊

Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.

Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.

Właściciele instytucjonalni (13F) 1 691 emitentów · $37.7B łącznie · Na dzień 30 czerwca 2026

Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.

Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
Nowe pozycje Zamknięte pozycje Zwiększone Zmniejszony Zmiana liczby akcji netto
161 (-79 vs poprzedni kw.) 315 (+42 vs poprzedni kw.) 606 (-84 vs poprzedni kw.) 607 (-23 vs poprzedni kw.) +23.3M

Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.

Instytucja Wartość Akcje % z śledzonych 13F Typ
VANGUARD CAPITAL MANAGEMENT LLC $4 143 696 762 97 087 553 10,98% Akcje
STATE STREET CORP $2 992 345 845 70 111 196 7,93% Akcje
PRIMECAP MANAGEMENT CO/CA/ $2 156 232 608 50 520 914 5,72% Akcje
VANGUARD PORTFOLIO MANAGEMENT LLC $1 271 556 448 29 792 794 3,37% Akcje
FMR LLC $1 239 549 312 29 042 861 3,29% Akcje
GEODE CAPITAL MANAGEMENT, LLC $1 212 072 881 28 557 132 3,21% Akcje
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $994 184 207 23 293 913 2,64% Akcje
NORGES BANK $903 536 838 21 170 029 2,40% Akcje
TWO SIGMA INVESTMENTS, LP $826 243 102 19 359 023 2,19% Akcje
Capital World Investors $717 600 310 16 812 257 1,90% Akcje
JANE STREET GROUP, LLC $686 580 356 16 086 700 1,82% Opcja kupna
WELLINGTON MANAGEMENT GROUP LLP $633 296 809 14 838 257 1,68% Akcje
Capital Research Global Investors $605 255 716 14 180 571 1,60% Akcje
TWO SIGMA ADVISERS, LP $600 558 161 6 298 460 1,59% Akcje
FARALLON CAPITAL MANAGEMENT, L.L.C. $449 044 133 10 521 184 1,19% Akcje
CANADA PENSION PLAN INVESTMENT BOARD $395 319 403 9 262 404 1,05% Akcje
Qube Research & Technologies Ltd $381 720 146 8 943 771 1,01% Akcje
VANGUARD FIDUCIARY TRUST CO $356 182 867 8 345 428 0,94% Akcje
BNP PARIBAS FINANCIAL MARKETS $325 241 617 7 620 469 0,86% Akcje
MORGAN STANLEY $278 890 927 6 534 464 0,74% Akcje
D. E. Shaw & Co., Inc. $254 250 351 5 957 131 0,67% Akcje
MAVERICK CAPITAL LTD $253 414 762 5 937 553 0,67% Akcje
Ensign Peak Advisors, Inc $251 016 744 5 881 367 0,67% Akcje
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $243 577 742 3 881 717 0,65% Akcje
UBS Group AG $240 594 117 5 637 163 0,64% Akcje
JANE STREET GROUP, LLC $238 521 448 5 588 600 0,63% Opcja sprzedaży
BlackRock, Inc. $234 043 121 5 483 672 0,62% Akcje
LAZARD ASSET MANAGEMENT LLC $227 443 076 5 329 032 0,60% Akcje
Clearbridge Investments, LLC $218 981 454 5 130 774 0,58% Akcje
JARISLOWSKY, FRASER Ltd $214 082 478 2 192 794 0,57% Akcje
BANK OF AMERICA CORP /DE/ $211 692 928 4 960 003 0,56% Akcje
MILLENNIUM MANAGEMENT LLC $210 735 360 5 437 567 0,56% Akcje
DIMENSIONAL FUND ADVISORS LP $208 893 933 4 894 422 0,55% Akcje
1832 Asset Management L.P. $194 487 468 4 556 876 0,52% Akcje
Holocene Advisors, LP $180 429 700 4 227 500 0,48% Opcja kupna
Swiss National Bank $178 906 024 4 191 800 0,47% Akcje
JANE STREET GROUP, LLC $178 652 846 4 185 868 0,47% Akcje
Assenagon Asset Management S.A. $178 127 498 4 173 559 0,47% Akcje
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ $170 906 014 4 042 830 0,45% Akcje
National Pension Service $168 995 643 3 959 598 0,45% Akcje
Legal & General Group Plc $160 927 972 3 770 571 0,43% Akcje
Mitsubishi UFJ Asset Management Co., Ltd. $154 393 705 3 617 472 0,41% Akcje
Ninety One UK Ltd $149 464 716 3 501 985 0,40% Akcje
Sumitomo Mitsui Trust Group, Inc. $146 301 705 3 427 875 0,39% Akcje
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $144 322 114 2 299 954 0,38% Akcje
Employees Provident Fund Board $143 349 316 3 358 700 0,38% Akcje
Vanguard Global Advisers, LLC $142 456 877 3 337 790 0,38% Akcje
VOLORIDGE INVESTMENT MANAGEMENT, LLC $139 790 914 3 275 326 0,37% Akcje
SUSQUEHANNA INTERNATIONAL GROUP, LLP $135 035 252 3 163 900 0,36% Opcja kupna
BNP PARIBAS ASSET MANAGEMENT Holding S.A. $134 976 349 3 162 285 0,36% Akcje
Caisse de depot et placement du Quebec $133 178 416 3 120 394 0,35% Akcje
Alecta Tjanstepension Omsesidigt $133 002 390 3 117 000 0,35% Akcje
Mirova US LLC $132 371 081 3 101 478 0,35% Akcje
BARCLAYS PLC $131 524 822 3 081 650 0,35% Akcje
VANGUARD ASSET MANAGEMENT, Ltd $122 627 792 2 873 191 0,33% Akcje
Public Sector Pension Investment Board $119 712 961 2 804 896 0,32% Akcje
MANUFACTURERS LIFE INSURANCE COMPANY, THE $115 346 242 2 702 583 0,31% Akcje
RHUMBLINE ADVISERS $112 753 784 2 641 843 0,30% Akcje
Rathbones Group PLC $108 402 974 2 539 901 0,29% Akcje
RENAISSANCE TECHNOLOGIES LLC $102 944 373 2 412 005 0,27% Akcje
Temasek Holdings (Private) Ltd $102 407 502 2 399 426 0,27% Akcje
Pictet Asset Management Holding SA $102 158 094 2 393 080 0,27% Akcje
Unisphere Establishment $101 911 304 2 387 800 0,27% Akcje
MILFORD FUNDS LTD $92 593 577 2 169 484 0,25% Akcje
ALLIANCEBERNSTEIN L.P. $91 340 092 1 455 619 0,24% Akcje
HSBC HOLDINGS PLC $90 846 130 2 128 541 0,24% Akcje
GOLDMAN SACHS GROUP INC $89 773 112 2 103 400 0,24% Opcja kupna
NOMURA HOLDINGS INC $88 556 732 2 074 900 0,23% Opcja kupna
Cubist Systematic Strategies, LLC $88 171 996 903 124 0,23% Akcje
NEUBERGER BERMAN GROUP LLC $87 691 368 2 054 624 0,23% Akcje
California Public Employees Retirement System $87 402 153 2 047 848 0,23% Akcje
Phoenix Financial Ltd. $82 560 747 1 934 413 0,22% Akcje
Nuveen Asset Management, LLC $76 820 023 860 054 0,20% Akcje
NEW YORK STATE COMMON RETIREMENT FUND $73 919 754 1 731 953 0,20% Akcje
SUSQUEHANNA INTERNATIONAL GROUP, LLP $73 776 648 1 728 600 0,20% Opcja sprzedaży
FIRST MANHATTAN CO. LLC. $72 442 215 1 697 334 0,19% Akcje
ADAGE CAPITAL PARTNERS GP, L.L.C. $71 276 539 1 670 022 0,19% Akcje
Banque Transatlantique SA $71 260 298 914 874 0,19% Akcje
PRINCIPAL FINANCIAL GROUP INC $70 441 674 1 650 461 0,19% Akcje
ROYAL BANK OF CANADA $70 272 000 1 646 479 0,19% Akcje
Squarepoint Ops LLC $69 351 970 1 624 929 0,18% Akcje
D. E. Shaw & Co., Inc. $68 616 636 1 607 700 0,18% Opcja sprzedaży
GROUPAMA ASSET MANAGMENT $68 098 768 1 571 750 0,18% Akcje
Lansforsakringar Fondforvaltning AB (publ) $67 481 689 1 581 108 0,18% Akcje
Walleye Capital LLC $67 356 381 1 578 172 0,18% Akcje
Squarepoint Ops LLC $66 922 240 1 568 000 0,18% Opcja kupna
VANGUARD GROUP INC $66 616 468 698 652 0,18% Akcje
GOLDMAN SACHS GROUP INC $65 853 458 1 542 958 0,17% Akcje
CAPITAL FUND MANAGEMENT S.A. $63 426 577 1 486 096 0,17% Akcje
ORBIMED ADVISORS LLC $63 302 976 1 483 200 0,17% Akcje
TUDOR INVESTMENT CORP ET AL $63 065 547 1 477 637 0,17% Akcje
CAXTON ASSOCIATES LP $62 622 699 701 105 0,17% Akcje
ENVESTNET ASSET MANAGEMENT INC $62 259 456 1 458 786 0,17% Akcje
AVIVA PLC $61 094 158 1 431 447 0,16% Akcje
Navera Investment Management Ltd. $60 925 063 1 427 592 0,16% Akcje
Connor, Clark & Lunn Investment Management Ltd. $60 808 373 1 424 751 0,16% Akcje
JONES FINANCIAL COMPANIES LLLP $56 948 391 1 287 551 0,15% Akcje
MENORA MIVTACHIM HOLDINGS LTD. $56 913 780 1 333 500 0,15% Akcje
Schonfeld Strategic Advisors LLC $56 634 266 1 326 951 0,15% Akcje
DEERFIELD MANAGEMENT COMPANY, L.P. $56 124 200 1 315 000 0,15% Akcje

Insiderzy spółki 90 insiderów · 30 dyrektorzy generalni · 18 dyrektorzy

Insider Rola Ostatnia aktywność Posiadane akcje Kupna 12m Sprzedaże 12m Netto 12m
William Kucheman Chief Executive Officer 31 lipca 2012 P 112 525 0 0 $0
James R Tobin President & CEO 24 lutego 2009 A 550 000 0 0 $0
Jeffrey D Capello EVP & Chief Financial Officer 27 listopada 2013 S 447 0 0 $0
Paul A Laviolette COO 1 lipca 2008 M 63 072 0 0 $0
Joseph Michael Fitzgerald EVP & Group Pres, Cardiology 31 lipca 2026 I 64 198 0 7 $-15 168 204
Karen Prange SVP&Pres, Uro & Pelvic Health 8 marca 2016 S 38 395 0 0 $0
Jean Fitterer Lance SVP, Asst GC, Bus & Regions 16 lutego 2015 M 117 174 0 0 $0
John Michael Onuscheck SVP & President, Europe 1 stycznia 2015 M 116 025 0 0 $0
Kenneth Pucel EVP, Glob Ops, Qual & Tech 28 lutego 2014 M 128 517 0 0 $0
Otha T. Spriggs III SVP, Human Resources 7 września 2012 M 12 738 0 0 $0
Lawrence R Neumann SVP, Special Projects 10 maja 2012 M 77 879 0 0 $0
Brian R Burns EVP - Global Quality & Reg Aff 28 lutego 2012 M 79 418 0 0 $0
John B. Pedersen Pres, Uro & Women's Health 16 lutego 2012 M 3 233 0 0 $0
Stephen F Moreci SVP, Global Sales Operations 1 lipca 2011 M 37 362 0 0 $0
Sam R Leno EVP & Chief Operations Officer 6 czerwca 2011 M 432 240 0 0 $0
Fred Colen EVP & Chief Technology Officer 10 maja 2010 M 72 497 0 0 $0
James Gilbert EVP, Strategy & Business Dev 26 lutego 2010 A 67 613 0 0 $0
David W Mcfaul SVP, International 12 lutego 2010 M 41 426 0 0 $0
Donovan Paul SVP, Corporate Communications 12 lutego 2010 M 33 103 0 0 $0
William F Mcconnell JR SVP, Administration CRM 24 lipca 2009 M 55 204 0 0 $0
Donald S Baim EVP, Chief Med. & Sci. Officer 10 lipca 2009 M 51 756 0 0 $0
Lucia Luce Quinn Exec. Vice President-HR 1 lipca 2009 M 49 809 0 0 $0
Paul W Sandman EVP and General Counsel 29 lutego 2008 M 66 846 0 0 $0
Jeffrey H Goodman SVP, International 1 lipca 2007 M 10 460 0 0 $0
Lawrence C Best EVP 1 lipca 2007 F 242 189 0 0 $0
Mark C Bartell SVP Global Sales/Mkt CRM 25 maja 2007 M 1 812 0 0 $0
Mary E Russell SVP and CMO 3 stycznia 2006 D 4 706 0 0 $0
James H Taylor JR Sr. VP, Operations 9 lutego 2005 M 9 360 0 0 $0
Dennis A Ocwieja SVP, Regulatory 3 stycznia 2005 A — 0 0 $0
Robert G Maclean SVP, HR 3 stycznia 2005 A 36 502 0 0 $0
Edward J Ludwig Dyrektor 31 lipca 2026 P 30 359 2 0 $430 314
JOHNSON KRISTINA M Dyrektor 3 maja 2016 A 8 494 0 0 $0
Nicholas J Nicholas JR Dyrektor 1 kwietnia 2016 A 0 0 0 $0
NICHOLAS PETER M Dyrektor 1 kwietnia 2016 A 3 486 965 0 0 $0
Ernest Mario Dyrektor 16 listopada 2015 S 86 032 0 0 $0
Uwe E Reinhardt Dyrektor 31 października 2014 A 159 379 0 0 $0
Bruce L Byrnes Dyrektor 31 października 2014 A 112 097 0 0 $0
Katharine T Bartlett Dyrektor 7 maja 2013 A 52 464 0 0 $0
John Raymond Elliott Dyrektor 27 lutego 2012 A 603 676 0 0 $0
Ray J Groves Dyrektor 31 marca 2011 A 1 000 0 0 $0
Marye Anne Fox Dyrektor 11 maja 2010 A 21 111 0 0 $0
John E Pepper Dyrektor 31 marca 2010 A 58 807 0 0 $0
Ursula M Burns Dyrektor 5 maja 2009 A 32 001 0 0 $0
Warren B Rudman Dyrektor 5 maja 2009 A — 0 0 $0
Nancy Ann Deparle Dyrektor 6 maja 2008 A 13 886 0 0 $0
Joel Lawrence Fleishman Dyrektor 6 maja 2008 A 125 691 0 0 $0
PROMERICA LP Posiadacz 10% 7 sierpnia 2007 J 54 635 185 0 0 $0
Emily Woodworth — 11 sierpnia 2026 I 2 930 0 0 $0
Jonathan Monson — 10 sierpnia 2026 I 9 908 0 0 $0
David C Habiger — 5 sierpnia 2026 P 17 160 5 0 $407 941

Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S

Aktywiści i właściciele 5%+ 7 akcji

Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.

Zgłaszający Złożono Udział Status Cel Zgłoszenie
Boston Scientific Corporation, Boston Scientific Scimed, Inc. 25 kwietnia 2008 — Pierwotne zgłoszenie M&A / sprzedaż SEC
GUIDANT CORPORATION ( 3 lutego 2006 — Pierwotne zgłoszenie M&A / sprzedaż SEC
Niezgłoszona osoba raportująca 14 lutego 2003 — Pierwotne zgłoszenie — SEC
Niezgłoszona osoba raportująca 14 lutego 2003 — Pierwotne zgłoszenie — SEC
Niezgłoszona osoba raportująca 27 czerwca 2002 — Pierwotne zgłoszenie — SEC
Niezgłoszona osoba raportująca 23 maja 2002 — Pierwotne zgłoszenie M&A / sprzedaż SEC
Niezgłoszona osoba raportująca 9 lipca 2001 — Pierwotne zgłoszenie M&A / sprzedaż SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Posiadanie ETF-ów Posiadane przez 211 funduszy ETF

Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.

Fundusz Waga Jednostki Na dzień Źródło
IHI · iShares Trust 4,12% 2 873 679 SH 21 sierpnia 2026 Dziennie
GDOC · Goldman Sachs ETF Trust 3,78% 15 740 NS 31 maja 2026 N-PORT
AGNG · Global X Funds 2,44% 41 335 NS 31 maja 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 2,04% 3 946 NS 30 kwietnia 2026 N-PORT
HTEC · EXCHANGE TRADED CONCEPTS TRUST 1,68% 15 586 NS 30 kwietnia 2026 N-PORT
POWA · Invesco Exchange-Traded Self-Indexe… 1,66% 59 686 SH 21 sierpnia 2026 Dziennie
RUNN · Strategic Trust 1,54% 109 930 NS 31 maja 2026 N-PORT
RSPH · Invesco Exchange-Traded Fund Trust 1,48% 245 399 SH 21 sierpnia 2026 Dziennie
FMED · Fidelity Covington Trust 1,44% 12 185 NS 31 maja 2026 N-PORT
HRTS · Tema ETF Trust 1,42% 15 285 NS 31 maja 2026 N-PORT
MDEV · First Trust Exchange-Traded Fund VI 1,42% 637 NS 30 czerwca 2026 N-PORT
SPGP · Invesco Exchange-Traded Fund Trust 1,40% 648 801 SH 21 sierpnia 2026 Dziennie
FHLC · FIDELITY COVINGTON TRUST 1,38% 683 394 NS 30 kwietnia 2026 N-PORT
CURE · Direxion Shares ETF Trust 1,23% 29 571 NS 30 kwietnia 2026 N-PORT
IYH · iShares Trust 1,13% 884 504 SH 21 sierpnia 2026 Dziennie
MEDI · Harbor ETF Trust 1,10% 5 252 NS 30 kwietnia 2026 N-PORT
RXL · ProShares Trust 1,04% 15 464 NS 31 maja 2026 N-PORT
RND · First Trust Exchange-Traded Fund VI 1,03% 1 162 NS 30 czerwca 2026 N-PORT
ESLG · Strategy Shares 0,97% 3 256 NS 30 kwietnia 2026 N-PORT
VHT · VANGUARD WORLD FUND 0,93% 4 467 628 SH 19 sierpnia 2026 Dziennie
ANEW · ProShares Trust 0,92% 1 476 NS 31 maja 2026 N-PORT
IXJ · iShares Trust 0,89% 781 782 SH 21 sierpnia 2026 Dziennie
KNO · INVESTMENT MANAGERS SERIES TRUST II 0,88% 9 340 NS 30 czerwca 2026 N-PORT
GURU · Global X Funds 0,83% 8 375 NS 30 kwietnia 2026 N-PORT
AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… 0,79% 14 552 NS 30 kwietnia 2026 N-PORT
PSET · Principal Exchange-Traded Funds 0,74% 5 002 NS 30 czerwca 2026 N-PORT
ESLV · Strategy Shares 0,66% 1 338 NS 30 kwietnia 2026 N-PORT
DTEC · ALPS ETF Trust 0,63% 9 723 NS 31 maja 2026 N-PORT
ESUM · Strategy Shares 0,62% 16 531 NS 30 kwietnia 2026 N-PORT
NBGX · Neuberger Berman ETF Trust 0,60% 1 844 NS 31 maja 2026 N-PORT
IIGD · Invesco Exchange-Traded Self-Indexe… 0,56% 160 000 21 sierpnia 2026 Dziennie
FFLC · FIDELITY COVINGTON TRUST 0,54% 105 660 NS 30 kwietnia 2026 N-PORT
ZECP · Zacks Trust 0,52% 36 519 NS 31 maja 2026 N-PORT
VFVA · VANGUARD WELLINGTON FUND 0,46% 91 846 SH 19 sierpnia 2026 Dziennie
FFLG · FIDELITY COVINGTON TRUST 0,46% 46 964 NS 30 kwietnia 2026 N-PORT
THMZ · Lazard Active ETF Trust 0,45% 5 654 NS 30 czerwca 2026 N-PORT
INFO · Harbor ETF Trust 0,43% 57 055 NS 30 kwietnia 2026 N-PORT
XOEF · iShares Trust 0,40% 1 861 SH 21 sierpnia 2026 Dziennie
CATH · Global X Funds 0,40% 83 468 NS 30 kwietnia 2026 N-PORT
RCGE · EA Series Trust 0,39% 6 410 NS 30 kwietnia 2026 N-PORT
JGLO · J.P. Morgan Exchange-Traded Fund Tr… 0,39% 477 916 NS 30 kwietnia 2026 N-PORT
FWD · AB Active ETFs, Inc. 0,39% 230 737 NS 31 maja 2026 N-PORT
SNPG · DBX ETF Trust 0,38% 1 068 NS 29 maja 2026 N-PORT
FXH · First Trust Exchange-Traded AlphaDE… 0,37% 56 542 NS 30 kwietnia 2026 N-PORT
KRMA · Global X Funds 0,36% 8 982 NS 31 maja 2026 N-PORT
HELO · J.P. Morgan Exchange-Traded Fund Tr… 0,36% 250 378 NS 30 kwietnia 2026 N-PORT
CRTC · DBX ETF Trust 0,33% 8 980 NS 31 maja 2026 N-PORT
BSCU · Invesco Exchange-Traded Self-Indexe… 0,30% 8 685 000 21 sierpnia 2026 Dziennie
OEI · Listed Funds Trust 0,29% 2 132 NS 30 kwietnia 2026 N-PORT
CAPE · DoubleLine ETF Trust 0,29% 16 211 NS 30 czerwca 2026 N-PORT